FeesSafety
Pluang+

Investigation launched into Orthofix Medical for possible fiduciary breaches affecting shareholders

Market News
09 Oct 2026, 02:35 WIB
PRNewsWire
View Source
Bearish
Investigation launched into Orthofix Medical for possible fiduciary breaches affecting shareholders

Levi & Korsinsky law firm has started an investigation into Orthofix Medical Inc. over potential breaches of fiduciary duties. This legal probe could impact current shareholders as it addresses possible financial misconduct by the company's management. Shareholders can seek more information or legal assistance from the firm at no cost. The investigation highlights concerns about corporate governance and investor protection at Orthofix Medical.

The investigation into Orthofix Medical Inc. is the subject of this update, providing context for readers interested in related market activity. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 09, 2026 05:21 WIB: of 128 priced US health-sector stocks, 51 rose and 77 fell today. Notable movers include SMMT at USD 17.19 with a -4.23% change and a typical hold time of 16 days, CGC at USD 0.84 down 4.20% with a 39-day hold, and AHCO at USD 6.10 up 3.74%, with Pluang order activity showing 75% sell and 25% buy, and a 17-day typical hold time.

More News

Nvidia posts triple-digit revenue growth but stock struggles amid leadership and regulatory concerns.

Nvidia posts triple-digit revenue growth but stock struggles amid leadership and regulatory concerns.

Nvidia reported exceptional third-quarter earnings with revenue and profits more than doubling year-over-year, driven by strong demand for its AI infrastructure. However, the stock price remains subdued due to uncertainty following founder Jensen Hua...

Company Fundamentals
Neutral
42 minutes ago
Phathom reports $84.7M Q3 revenue, $0 copay for VOQUEZNA, and reaffirms 2026 revenue guidance.

Phathom reports $84.7M Q3 revenue, $0 copay for VOQUEZNA, and reaffirms 2026 revenue guidance.

Phathom Pharmaceuticals reported third-quarter net revenues of $84.7 million, driven by strong sales of VOQUEZNA, its treatment for GERD. The company introduced a $0 copay program through BlinkRx for commercially insured patients to boost access and ...

Company Fundamentals
Bullish
44 minutes ago
Target boosts store traffic 5.6% and food sales nearly 7% in Q3 2026 with tech-driven inventory upgrades.

Target boosts store traffic 5.6% and food sales nearly 7% in Q3 2026 with tech-driven inventory upgrades.

In Q3 2026, Target reported a 5.6% increase in comparable store sales and nearly 7% growth in food and beverage sales, driven by stronger customer visits and expanded automated inventory replenishment covering over 90% of products. Management is simp...

Company Fundamentals
Bullish
48 minutes ago
KBR's Q3 revenue rises 5% with record $5.8B tech backlog; plans Trinzic spin-off on Jan 4, 2027

KBR's Q3 revenue rises 5% with record $5.8B tech backlog; plans Trinzic spin-off on Jan 4, 2027

KBR reported a 5% revenue increase in Q3 2026 to $2.03 billion, driven by growth in its commercial technology business. The company's sustainable tech backlog hit a record $5.8 billion, up over 50% year-over-year, providing strong revenue visibility....

Company Fundamentals
Bullish
59 minutes ago
John B. Sanfilippo sees contract manufacturing growth offset retail losses amid industry shifts

John B. Sanfilippo sees contract manufacturing growth offset retail losses amid industry shifts

John B. Sanfilippo reported a 41.3% increase in contract manufacturing volume, offsetting declines in private brand retail sales due to changes in sourcing by key partners. The company is investing in high-speed production lines to expand private lab...

Company Fundamentals
Bullish
59 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App